EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Canagliflozin Alleviates Experimental ANCA-Associated Vasculitis through Suppression of Pathogenic T-Cell Responses

Xiang-Yu Han, Zhi-Ying Li, Su-Fang Chen, Ming-Hui Zhao, Mark A. Little, Min Chen

Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2407-2420

DOI: 10.1681/asn.0000001137 ↗
AbstractBibliografische Angaben

Abstract

Key Points Canagliflozin ameliorated experimental ANCA-associated vasculitis through broad suppression of pathogenic T-cell subsets. The immunomodulatory effect of canagliflozin was mediated in part by inhibition of p38 mitogen-activated protein kinase signaling in T cells. Background The nephroprotective role of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been well established by several randomized controlled trials involving patients with diabetic and nondiabetic CKD. However, the impact of SGLT2 inhibitors on ANCA-associated vasculitis (AAV) and the underlying mechanisms remain unclear. Methods The therapeutic effects of canagliflozin were evaluated in a rat model of experimental AAV. RNA sequencing was performed on the kidney and lymph nodes. In parallel, mechanistic studies were conducted in mouse models. Myeloperoxidase-deficient ( Mpo −/− ) mice were immunized with mouse myeloperoxidase and treated with canagliflozin. Splenocytes from these donors were then adoptively transferred into recombinase-activating gene-1–deficient ( Rag1 −/− ) mice. Comprehensive immune phenotyping by flow cytometry, enzyme-linked immunospot assays, and in vitro differentiation of human T cells were employed to dissect the immunomodulatory effects and underlying mechanisms. Results Canagliflozin alleviated kidney injury, pulmonary hemorrhage, and T-lymphocyte infiltration in AAV rats. Renal transcriptomic analysis showed a suppression of adaptive immunity pathways. In the adoptive transfer model, canagliflozin treatment of donor mice led to a significant reduction in splenic Th1, Th17, and CD8 + T cells, accompanied by a markedly diminished capacity of splenocytes to secrete IFN- γ and IL-17A upon restimulation. Transfer of these modulated splenocytes conferred significant nephroprotection to recipient mice. In vitro , canagliflozin suppressed the differentiation of primary CD4 + T cells from patients with AAV into both Th1 and Th17 lineages, but did not directly affect B-cell activation or antibody production. Mechanistically, canagliflozin inhibited the phosphorylation of both p38 and extracellular signal-regulated kinase mitogen-activated protein kinases in activated T cells, and the suppressive effect on cytokine production was partially reversed by activation of the p38 mitogen-activated protein kinase pathway. Conclusions Canagliflozin alleviated experimental AAV by suppressing pathogenic T cell effector responses—an effect mechanistically linked to inhibition of the p38 signaling pathway.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →